Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Details for Australian Patent Application No. 2010276460 (hide)

International Classifications

Event Publications

10 February 2011 Complete Application Filed

Priority application(s): 9800569 12.01.98 GB

17 February 2011 Application Open to Public Inspection

Published as AU-A-2010276460

21 April 2011 Standard Patent Sealed

26 May 2011 Extension of Term of Standard Patents

GlaxoSmithKline LLC The earliest first regulatory approval date provided by the patentee 28 Jun 2007 For the goods TYKERB lapatinib Applications Accepted The following application(s) for Extension of Term have been accepted under Section 74. Notice of opposition under Section 75(1) to the undermentioned application(s) for an extension of term may be filed at the Patent Office within the prescribed time.

11 August 2011 Licence Registered

GlaxoSmithKline LLC ( SmithKline Beecham (Cork) Limited ) Mortgages Registered - Section 187, Reg. 19 (The name in the parentheses is that of the mortgagee)

29 March 2012 Extension of Term of Standard Patents

GlaxoSmithKline LLC The earliest first regulatory approval date provided by the patentee 28 Jun 2007 For the goods TYKERB lapatinib Address for service in Australia: Davies Collison Cave 1 Nicholson Street Melbourne VIC 3000

30 August 2012 Extension granted

GlaxoSmithKline LLC The earliest first regulatory approval date provided by the patentee 28 Jun 2007 For the goods TYKERB lapatinib Extension of Term of patent pursuant to Section 77 expires on 28 Jun 2022

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.